Intuitive Surgical upgraded to Buy from Neutral at Goldman Goldman upgraded Intuitive Surgical and believes general surgery uptake will be the next leg of growth as surgical robotics evolves. The firm said the new da Vinci, upgrades, and add-ons will accelerate growth and that there is potential for management to return excess cash to shareholders. Price target raised to $715 from $591.
Intuitive Surgical initiated with an Overweight, $575 target at Barclays Barclays analyst Matthew Taylor started shares of Intuitive Surgical with an Overweight rating and $575 price target. Taylor thinks surgery share will continue to shift to robotic and believes demand for Intuitive's da Vinci among general surgeons is very high. The stock closed yesterday down $4.17 to $492.45.